StockData
Alto Neuroscience, Inc. logo

Alto Neuroscience, Inc. (ANRO) stock

ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$26.51+0.60 (+2.32%)

Close on Nov 19, 2026Market cap $1.04BP/E –Yield –

Alto Neuroscience free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Alto Neuroscience's free cash flow for the twelve months ending Sep 30, 2026 was -$79.68M. For fiscal 2025 it was -$51.79M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$51.79M–
FY2024Dec 31, 2024-$49.50M–
FY2023Dec 31, 2023-$33.92M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$20.76M–
Q2 FY2026Jun 30, 2026-$19.76M–
Q1 FY2026Mar 31, 2026-$27.65M–
Q4 FY2025Dec 31, 2025-$11.52M–
Q3 FY2025Sep 30, 2025-$9.92M–
Q2 FY2025Jun 30, 2025-$13.78M–
Q1 FY2025Mar 31, 2025-$16.58M–
Q4 FY2024Dec 31, 2024-$13.53M–
Q3 FY2024Sep 30, 2024-$12.73M–
Q2 FY2024Jun 30, 2024-$12.03M–
Q1 FY2024Mar 31, 2024-$11.21M–
Q4 FY2023Dec 31, 2023-$11.88M–
Q3 FY2023Sep 30, 2023-$7.81M–
Q2 FY2023Jun 30, 2023-$6.69M–
Q1 FY2023Mar 31, 2023-$7.55M–

More Alto Neuroscience figures

See a number that looks wrong?